Summary A recent wave of consolidation announcements is signaling a major turning point for SMOs operating throughout the United States. This juncture marks a divergence in strategic directions taken by large and established SMOs. A growing number of investigative sites will see protocols designed to determine gender differences. Sites with expertise in conducting women's health studies can expect strong growth in the coming three to five years.
European doctors seem to have little interest in the commercial aspect of clinical trials.
Physicians do not want to refer patients to specialists for fear of losing the income from those patients, and investigators may have to pay extra taxes. Macular degeneration is caused by the deterioration of the central area of the retina, the macula, that is responsible for focusing central vision in the eye. Since current treatments can't restore lost vision, scientists are trying to develop drugs that will slow down or reduce vision loss in early stage patients with macular degeneration.